IN8bio stock centers on clinical programs. The Nasdaq listing stays the key anchor.

IN8bio stock is framed by its clinical-stage cancer pipeline and Nasdaq listing, with no live catalyst surfaced in the available results. The company remains focused on cell therapy development and investor attention stays tied to trial progress.

By Christina Vaughn, Background & Management desk. Reviewed on July 3, 2026 at 6:45 p.m. ET.

IN8bio, Inc. (US45332Y1001) is a clinical-stage biotechnology company best known for its work on gamma-delta T cell therapies, and the stock trades on the Nasdaq Capital Market under the ticker INAB. With no live search results available in this call, the most defensible frame is the company’s pipeline and its dependence on trial execution.

Clinical-stage setup

The company’s business model centers on developing cell therapies for cancer rather than selling an established commercial product. That means investors tend to focus on clinical updates, cash runway, and the timing of later-stage data readouts.

For a small biotech on Nasdaq, that mix can matter more than broad market noise. The share price often reflects the market’s latest view of development risk, not current revenue strength.

What investors track

In this kind of setup, each pipeline update can carry more weight than a normal quarterly print. Trial milestones, regulatory interactions, and financing decisions are the main variables that can reshape sentiment.

US-market context also matters because IN8bio is listed on Nasdaq, which keeps the stock inside a familiar reference set for retail traders and biotech watchers. That listing gives the name an immediate comparison group across other development-stage cancer stocks.

Pipeline focus

IN8bio's lead effort is built around engineered gamma-delta T cell programs for oncology, a niche that can appeal to investors looking for differentiated immunotherapy approaches. The company’s value case depends on whether those programs can move through development with enough safety and efficacy evidence to justify further capital.

Company and product

The representative product story here is the broader cell therapy platform rather than a consumer item. In practical terms, IN8bio is pitching a scientific platform aimed at cancer treatment, with the pipeline itself serving as the product engine.

Stock context

With no verified live quote in the available results, the cleanest stock read is the listing itself: IN8bio trades on Nasdaq as INAB. As of July 3, 2026, the latest verified price was not available in the provided search results.

Fact box

• Company: IN8bio, Inc.
• ISIN: US45332Y1001
• Ticker: INAB
• Exchange: Nasdaq Capital Market
• Sector / Industry: Biotechnology / Biotechnology

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.